Wall Street Zen Downgrades Repligen (NASDAQ:RGEN) to Hold

Repligen (NASDAQ:RGEN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Sunday.

Several other analysts also recently issued reports on RGEN. Royal Bank Of Canada cut their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research note on Wednesday, April 16th. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Finally, Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus target price of $172.83.

Repligen Trading Down 0.5%

Shares of NASDAQ RGEN opened at $123.56 on Friday. The company has a market cap of $6.94 billion, a price-to-earnings ratio of -274.58, a price-to-earnings-growth ratio of 3.54 and a beta of 1.10. Repligen has a 12-month low of $102.97 and a 12-month high of $182.52. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The stock's 50 day simple moving average is $128.10 and its 200 day simple moving average is $140.93.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $0.28 EPS. Equities research analysts expect that Repligen will post 1.72 EPS for the current year.

Hedge Funds Weigh In On Repligen

Hedge funds have recently modified their holdings of the company. Signaturefd LLC increased its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in shares of Repligen in the 4th quarter worth $29,000. Raiffeisen Bank International AG acquired a new position in shares of Repligen in the 4th quarter worth $29,000. Twin Tree Management LP acquired a new position in shares of Repligen in the 1st quarter worth $29,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Repligen in the 4th quarter worth $40,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.